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Abstract
Background: Succinic semialdehyde dehydrogenase (SSADH) deficiency is a rare neurometabolic disorder resulting
in a heterogeneous clinical phenotype. Adolescent and adult patients with SSADH deficiency may present with
OCD symptoms. There is minimal literature regarding the pathological basis of OCD symptoms and their
management amongst SSADH deficiency patients.
Case presentation: A 26-year-old woman with SSADH deficiency experienced obsessional slowness and hesitancy
in her activities of daily living, with motor rituals and stereotypies of her hands and face. Neuroimaging revealed T2
hyperintensities of the globi pallidi bilaterally. Commencement of the serotonergic escitalopram moderately
improved her OCD symptoms. The addition of the dopaminergic pramipexole hydrochloride yielded further
improvement, following unsuccessful trial of other adjuncts: risperidone, methylphenidate and mirtazapine.
Conclusions: Pallidal pathology may explain the manifestation of OCD symptoms amongst individuals with SSADH
deficiency. Serotonergic and concomitant dopaminergic therapy may be a viable treatment regimen for SSADH
deficiency patients presenting with OCD symptoms.
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Background
Succinic semialdehyde dehydrogenase (SSADH) defi-
ciency (OMIM #271980), also known as 4-
hydroxybutyric aciduria, is an autosomal recessive dis-
order in the degradation pathway of γ-aminobutyric acid
(GABA): the central nervous system’s predominant in-
hibitory neurotransmitter [1–3]. In SSADH deficiency,
there is an accumulation of the compound γ-
hydroxybutyric acid (GHB) (4-hydroxybutyric acid)
within the cerebrospinal fluid, serum and urine [1, 4].
Urinary organic acid analysis is used as a means of de-
tecting GHB and diagnosing SSADH [5]. Neuroimaging
is often useful as part of the diagnostic work-up. Mag-
netic resonance imaging (MRI) frequently reveals T2-
weighted hyperintensities involving the globi pallidi, sub-
cortical white matter, cerebellar dentate nuclei and
brainstem [5, 6]. A normal MRI may be observed in up
to 43% of cases [6]. Confirmation of diagnosis may be
achieved by genetic analysis of the ALDH5A1 gene en-
coding SSADH.
SSADH deficiency is rare, identified in approximately
450 patients worldwide [7]. SSADH deficiency has non-
specific symptomatology and a varied natural history
throughout the life course [2, 5, 6, 8–10]. Hence, SSAD
H deficiency is likely underdiagnosed [7, 9, 10]. In
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infancy and childhood, individuals with SSADH defi-
ciency typically present with global developmental delay,
hypotonia, epilepsy and ataxia [5, 8, 9]. In addition to
these clinical features, sleep disorders and neuropsychi-
atric symptoms are common manifestations in adoles-
cence and adulthood [6, 7, 9, 10]. Obsessive-compulsive
disorder (OCD) symptoms have previously been ob-
served in adolescents and adults [7, 9, 10]. Management
of SSADH deficiency patients remains largely symptom-
atic [7, 11]. Management of OCD symptoms in SSADH
deficiency patients remains unclear and is generally
guided by conventional guidelines for OCD treatment.
We describe the case of a 26-year-old woman with
SSADH deficiency who developed obsessive-compulsive
disorder (OCD)-like symptoms and our subsequent
management approach. This case provides a possible
framework for the management of future SSADH pa-
tients who present with similar symptoms.
Case presentation
Ms. A is a 26-year-old single unemployed woman re-
ferred to a tertiary Neuropsychiatry Unit for ongoing
management of neuropsychiatric symptoms of SSADH
deficiency. Delayed developmental milestones and sei-
zures were noted from an early age. At 4 years of age,
Ms. A was diagnosed with epilepsy and global develop-
mental delay of unknown aetiology. No further work-up
was conducted. She was treated with antiepileptic medi-
cation and early psychosocial intervention, attending
specialised primary and secondary schools.
At 12 years of age, Ms. A was diagnosed with SSADH
deficiency following the diagnosis of her younger brother
with the same condition. Her diagnosis was confirmed
via urinary organic acid quantification, with elevated 4-
hydroxybutyric acid and 4,5-dihydroxy hexanoic lactone
levels. Genotyping was not performed. Formal neuro-
psychological testing at the time revealed mild-to-
moderate intellectual disability.
From age 14, Ms. A experienced significant functional
decline with manifestation of worsening OCD symp-
toms. She displayed marked difficulties initiating tasks,
obsessional slowness and hesitancy in her activities of
daily living, particularly when toileting and eating result-
ing in incontinence and weight loss, driven by obses-
sional doubt (about whether she was eating correctly or
too quickly, had lifted her leg the correct way to put on
trousers), and fears that certain behaviours may result in
harm to her mother or brother. She exhibited motor rit-
uals, particularly regarding the placement of food uten-
sils and the correct “cutting” of food, and stereotypies of
her hands and face involving wiping and chewing. Meal-
times were particularly problematic: prefaced by 30 min
of pacing, 30–45min of ordering cutlery, and then 1–2 h
of slow mastication, marked by frequent pauses,
requiring prompting to continue. She denied intrusive
internal imagery. There were no religious or sexual pre-
occupations, counting or cleaning behaviours. Delusions
and hallucinations were not apparent. Ms. A also
showed increasing agitation and anxiety. When 22-
years-old, Ms. A was referred to the Neuropsychiatry
Unit for assessment and symptomatic management of
these symptoms. Her score on the Yale-Brown
Obsessive-Compulsive Scale (Y-BOCS) at initial assess-
ment was 33, denoting extreme OCD (0–13 mild, 14–25
moderate, 26–34 moderate-severe OCD; 35–40 severe
OCD) [12]. On mental state, she was well-groomed and
politely-engaged. She had markedly reduced eye contact
and a mild fine tremor of her upper limbs. Her speech
was slow, had low tone and was mildly dystonic. Her
vocalisations were slow, with long latency and were brief.
Her affect was restricted yet congruent with her mood.
There were no psychotic phenomena, yet she was pre-
occupied with internal cognitions of doubt and uncer-
tainty. Neurological examination revealed mildly
elevated tone, particularly on augmentation, with cog-
wheeling and hyperreflexia bilaterally. She demonstrated
occasional orobuccal lip-sucking movements and athe-
toid movements of the trunk. She had reduced arm
swing when walking, pedestal turning, with reduced foot
clearance and stride length. Eye movements showed
some saccadic intrusions into slow pursuit movements,
and saccadic over-and under-shoot requiring multiple
small corrections. Her only treatment at this time was
lamotrigine 75 mg bd.
Neuroimaging revealed significant increased T2 signal
in the pars interna and externa of the globi pallidi, sub-
stantiae nigrae and dentate nuclei bilaterally (Fig. 1).
Moderate volume loss was also evident involving primar-
ily the frontal lobe white matter, deep grey matter nu-
clei, brainstem and cerebellum.
Ms. A commenced the serotonergic medication escitalo-
pram, which was gradually up-titrated from 10mg to 70
mg od. This moderately improved her obsessional slow-
ness, psychomotor retardation and motor rituals. Spon-
taneity in initiating movements and complex activities
remained problematic. Her Y-BOCS scale decreased to 24
over 18months, and the duration of mealtimes halved.
Further attempts to optimise Ms. A’s residual OCD
symptoms were made: the adjuncts risperidone 0.5 mg
od, methylphenidate 5 mg od, mirtazapine 7.5 mg od
were added cumulatively. These medications offered no
benefit with her obsessive-compulsive phenomena.
These were discontinued in turn due to worsening extra-
pyramidal side effects, agitation and social withdrawal,
and hypersomnolence respectively. Conservative and
non-pharmacologic therapies were also trialled to man-
age Ms. A’s OCD symptoms to improve her obsessional
slowness and break compulsive rituals.
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At age 25, Ms. A’s anxiety improved using lorazepam
1mg bd. Shortly thereafter Ms. A commenced the dopa-
minergic pramipexole hydrochloride, up-titrated from
0.25 mg to 0.5 mg bd. This significantly improved her
obsessional slowness, motor initiation and psychomotor
speed, with a reduction in mealtime duration by a fur-
ther 50%. Further attempts to increase the dose of pra-
mipexole hydrochloride yielded increased initiation and
volition, yet increased Ms. A’s anxiety and agitation. She
continued with pramipexole hydrochloride 0.5 mg bd.
Ms. A had significant functional improvement in under-
taking her activities of daily living, increased social en-
gagement and a markedly increased hedonic response.
Discussion and conclusions
OCD symptoms are a relatively common neuropsychi-
atric manifestation of SSADH deficiency in adolescents
and adults. In their SSADH-deficient patient database
(n = 33), Knerr et al. [9] found 11 (33%) adolescents and
adults displayed OCD symptoms. Similarly, 12 (48%)
adults presented with OCD behaviours in Lapalme-
Remis’ et al. [10] analysis of their SSADH-deficient data-
base (n = 25).
Bilateral changes to the globi pallidi have been de-
scribed in SSADH deficiency, with macroscopic findings
including well-circumscribed pallidal discolouration and
hyperaemia [13]. These changes correspond with areas
of increased T2 signal in the globi pallidi on neuroimag-
ing [13], consistent with the findings reported in this pa-
tient. Pallidal pathology could be a possible explanation
for this patient’s presentation. The association between
pallidal pathology and development of OCD and other
compulsive disorders has been well-documented [14–
16], with disruption to the integrity of specific frontal-
subcortical tracts including the lateral orbitofrontal loop
[17] (Fig. 2). Excitatory glutamergic and inhibitory
GABAergic cortical tracts from the orbitofrontal cortex
and anterior cingulate cortex converge on the globus
pallidus via the striatum [18, 19]. Projections from the
globus pallidus to the thalamus and then back to the
cortex completes this neural circuit [18, 19]. When path-
ology of the globus pallidus occurs, this results in an im-
balance within these neural circuits [19]. This may thus
underpin our patient’s constellation of “inhibitory”
symptoms (obsessional slowness and hesitancy) and “ex-
citatory” symptoms (motor rituals, stereotypies and agi-
tation). It is possible that the degree of pallidal
pathology is associated with OCD symptom severity.
Despite the prevalence of OCD symptoms amongst
SSADH deficiency patients, there is a gap in knowledge
regarding the optimal management approach. Knerr
et al. [9] describe one individual whose anxiety and
OCD symptoms responded positively to fluoxetine 20
mg/day used concomitantly with methylphenidate 10–
20mg tds, risperidone 2mg bd and carbamazepine 20
mg/kg/day. To our knowledge, there is no other litera-
ture detailing OCD symptom response to management.
Our case also suggests benefit in using a selective sero-
tonin reuptake inhibitor: Ms. A had moderate
Fig. 1 Oblique axial FLAIR image demonstrating increased T2 signal
in the pars interna and externa of the globi pallidi (solid arrow
heads), substantiae nigrae (open arrow heads) and dentate
nuclei (arrows)
Fig. 2 Neural circuit. Lateral orbitofrontal loop, projecting from the
orbitofrontal cortex (OFC) via the ventromedial caudate and
substantia nigra (SN) to the globus pallidus (GP), then thalamus (Th.),
and back to the OFC
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improvement in her OCD symptoms using escitalopram.
Methylphenidate and risperidone provided no benefit.
Use of the stimulant methylphenidate also worsened Ms.
A’s comorbid agitation and anxiety. In this regard, we
hypothesised an anxiety-based obsessionality under-
pinned Ms. A’s OCD symptoms.
The dopamine agonist pramipexole hydrochloride was
added to address Ms. A’s constellation of OCD and
movement symptoms. This is the first report of the util-
ity of this agent in SSADH deficiency. Increasing prami-
pexole hydrochloride dose increased Ms. A’s motor
initiation and psychomotor speed, however, at the cost
of increased anxiety and agitation. This reaffirmed our
hypothesis of an anxiety-grounding to Ms. A’s obsessive-
compulsive phenomena.
OCD symptoms are a possible neuropsychiatric mani-
festation in individuals with SSADH deficiency. Overall,
our case suggests use of the serotonergic agent escitalo-
pram in conjunction with dopaminergic pramipexole
hydrochloride is a potentially effective symptomatic
treatment regimen in patients with SSADH deficiency
presenting with OCD symptoms. Dosage of pramipexole
hydrochloride should be titrated according to patient
symptoms and side effects. This is particularly important
in SSADH-deficient individuals who present with OCD
symptoms and anxiety, as their OCD symptoms may
have an anxiety-basis. This ensures OCD symptom opti-
misation whilst preventing increasing agitation. Further
studies into the management approach of OCD and
other neuropsychiatric symptoms in SSADH deficiency
patients are required. The management of this clinical
case demonstrates a possible treatment algorithm for
SSADH deficiency patients with OCD symptoms, sug-
gesting that serotonergic treatment is the mainstay, but
may be augmented by dopaminergic and other therapy
to reduce slowness without worsening anxiety or
agitation.
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